← Back to Search

Personalized Intervention for High Blood Pressure

N/A

Waitlist Available

Research Sponsored by Brigham and Women's Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 6 months following the intervention date

Awards & highlights

Study Summary

This trial is testing two interventions targeting clinical inertia in hypertension compared to control, followed by predictive modeling to identify factors associated with intervention responsiveness.

Who is the study for?

This trial is for primary care physicians at Massachusetts General Hospital who treat adults aged 18-79 with high blood pressure. These patients should have had a BP over 140/90 mmHg during two or more visits in the past year without intensified treatment. Physicians must see at least two such patients and not be part-time or managing fewer than 100 patients.Check my eligibility

What is being tested?

The study tests if pharmacist e-detailing or provider dashboards can help manage high blood pressure better compared to no intervention. After these methods are applied, interviews and predictive modeling will identify which factors influence whether a physician intensifies hypertension treatment when needed.See study design

What are the potential side effects?

Since this trial involves non-medical interventions like information detailing and feedback systems, there are no direct medical side effects to participants. However, changes in how doctors manage high blood pressure could indirectly affect patient health outcomes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 6 months following the intervention date

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 6 months following the intervention date

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months following the intervention date for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Treatment Intensification

Secondary outcome measures

Change in systolic blood pressure

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Pharmacist E-DetailingExperimental Treatment1 Intervention

A pharmacist will review the chart in advance and provide a personalized recommendation for how to intensify the specific patient's antihypertensive regimen based on current guidelines. For example, they might recommend adding an additional medication based on the patient's comorbid conditions and could suggest a starting dose and timeframe for dose escalation.

Group II: Audit and FeedbackExperimental Treatment1 Intervention

A report of the provider's hypertension control rates compared to benchmark will be displayed using principles of social norming. We will present that provider's hypertension control rates compared to the 90th percentile of their peers.

Group III: ControlActive Control1 Intervention

No intervention will be provided to physicians in the control arm.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pharmacist E-Detailing

2021

N/A

~520

Audit and Feedback

2016

N/A

~85530

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor

1,608 Previous Clinical Trials

11,469,366 Total Patients Enrolled

National Institute on Aging (NIA)NIH

1,668 Previous Clinical Trials

28,004,553 Total Patients Enrolled

Media Library

Audit and Feedback Clinical Trial Eligibility Overview. Trial Name: NCT04603560 — N/A

High Blood Pressure Research Study Groups: Audit and Feedback, Pharmacist E-Detailing, Control

High Blood Pressure Clinical Trial 2023: Audit and Feedback Highlights & Side Effects. Trial Name: NCT04603560 — N/A

Audit and Feedback 2023 Treatment Timeline for Medical Study. Trial Name: NCT04603560 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this trial accept participants older than seventy-five years of age?

"For this trial to be successful, it needs participants aged above 18 years and below 79."

Answered by AI

Is this research initiative currently recruiting participants?

"According to clinicaltrials.gov, this particular trial has concluded recruitment since it was posted on October 26th 2021 and last updated November 9th 2022. Fortunately for patients seeking a medical study currently recruiting, there are 746 other trials accepting patient enrolment at the moment."

Answered by AI

Who is eligible to enroll in this clinical investigation?

"This medical trial is recruiting 505 individuals aged 18 to 79 with hypertension, and additional key criteria must be met. These include having a primary care physician at Massachusetts General Hospital who has been caring for 2 patients within the past 18 months whose blood pressure was above goal, and not having had their treatment regimens intensified in or following that time frame. Moreover, the BP target should be lower than 140/90 for all participants; due to pandemic-related changes in care delivery during 2020's COVID surge, both physical office visits as well as virtual appointments featuring same-day recorded vitals will also qualify."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Personalizing Intervention to Reduce Clinical Inertia in the Treatment of Hypertension

Nancy Haff, MD, MPH 2021. "Personalizing Intervention to Reduce Clinical Inertia in the Treatment of Hypertension". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04603560.